Analysis of Once-Daily Thoracic Radiotherapy Dose According to the Underlying Lung Disease in Patients with Limited-Stage Small Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy
Cancer Research and Treatment. 2023;55(1):73-82 
CONVERT: Concurrent once-daily versus twice-daily radiotherapy A phase III randomised controlled trial for patients with limited stage small cell lung cancer and good performance status
Lung Cancer. 2010;67:S11
CONVERT: Concurrent once-daily versus twice-daily radiotherapy – a new phase III randomised controlled trial for patients with limited-stage small cell lung cancer and good performance status
Lung Cancer. 2009;63:S12
167 CONVERT: Concurrent ONce-daily VErsus twice-daily RadioTherapy. A phase III randomised controlled trial for patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
Lung Cancer. 2012;75:S55
Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited-stage small cell lung cancer (LS-SCLC)
Lung Cancer. 2009;63:S11-S12
Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small cell lung cancer: a report of 134 patients
Lung Cancer. 1994;11:174
Concurrent platinum (CDDP)-etoposide (VP-16) chemotherapy plus thoracic radiotherapy (TRT) for limited stage small cell lung cancer (SCLC)
Lung Cancer. 1994;10:S337
Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin for limited stage small cell carcinoma of the lung (SCCL)
Lung Cancer. 1986;2(1-2):158
PO-1274 Is a once-daily RT dose optimal for patients with underlying lung disease in limited-stage SCLC?
Radiotherapy and Oncology. 2022;170:S1073
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
Cancer/Radiothérapie. 2000;4(4):319-320